{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:20Z","timestamp":1787021420505,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The PREVENT randomized clinical trial showed that bioimpedance spectroscopy (BIS) screening for subclinical breast-cancer-related lymphedema (sBCRL) detection with early intervention is associated with lower progression to chronic breast-cancer-related lymphedema (cBCRL) than tape measurement (TM). This study explores the role of a pre-treatment baseline in detecting sBCRL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 1200 patients with breast cancer were randomized for screening using L-Dex (BIS) or relative interlimb volume difference (RILVD) from TM, with 918 patients being monitored for up to 36 months. sBCRL was identified in 209 patients by either an increase from baseline of \u2265 6.5 L-Dex units (\n                      <jats:italic>n<\/jats:italic>\n                      = 89) or \u2265 5% and\u2009&lt;\u200910% increase in RILVD (\n                      <jats:italic>n<\/jats:italic>\n                      = 120). The pre-treatment and sBCRL trigger L-Dex and RILVD were analyzed using Mann\u2013Whitney, independent\n                      <jats:italic>t<\/jats:italic>\n                      -tests, chi-squared, and analysis of variance (ANOVA) tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The baseline L-Dex or RILVD was less than zero in 587 (48.9%) and 596 (49.0%) patients, respectively. At sBCRL trigger, 70.8% BIS patients had L-Dex inside the normal range (L-Dex\u2009&lt;\u200910), and 40.4% had L-Dex\u2009&lt;\u20096.5, which could result in misclassification without a pre-treatment baseline. For TM patients, 87.5% had an RILVD inside the normal range (RILVD\u2009&lt;\u200910%), and 51.7% had a RILVD\u2009&lt;\u20095%, which would also cause misclassification without a pre-treatment baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Many patients who triggered for sBCRL would not have been identified without a pre-treatment baseline, potentially missing opportunities for early intervention and increasing the risk of progression. Regardless of the measurement technique used, a recorded baseline is crucial for accurate detection and timely management of sBCRL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-17854-0","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T13:38:46Z","timestamp":1753277926000},"page":"8390-8397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema"],"prefix":"10.1245","volume":"32","author":[{"given":"Steven L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Boyages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Koelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Vicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila H.","family":"Ridner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"17854_CR1","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/cncr.23494","volume":"112","author":"NL Stout Gergich","year":"2008","unstructured":"Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112:2809\u201319.","journal-title":"Cancer."},{"key":"17854_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/lrb.2014.0035","volume":"12","author":"A Soran","year":"2014","unstructured":"Soran A, Ozmen T, McGuire KP, et al. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection: a prospective observational study. Lymphat Res Biol. 2014;12:289\u201394.","journal-title":"Lymphat Res Biol."},{"key":"17854_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/cncr.31873","volume":"125","author":"LA Koelmeyer","year":"2019","unstructured":"Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early Surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared with a traditional referral model of care. Cancer. 2019;125:854\u201362.","journal-title":"Cancer."},{"key":"17854_CR4","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1245\/s10434-019-07344-5","volume":"26","author":"SH Ridner","year":"2019","unstructured":"Ridner SH, Dietrich MS, Cowher MS, et al. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer: interim analysis. Ann Surg Oncol. 2019;26:3250\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"14","key":"17854_CR5","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1002\/cam4.3188","volume":"9","author":"SH Ridner","year":"2020","unstructured":"Ridner SH, Shah C, Boyages J, et al. L-Dex, arm volume, and symptom trajectories 24 months after breast cancer surgery. Cancer Med. 2020;9(14):5164\u201373.","journal-title":"Cancer Med."},{"key":"17854_CR6","first-page":"1081","volume":"29","author":"L Koelmeyer","year":"2021","unstructured":"Koelmeyer L, Gaitatzis K, Ridner SH, et al. Implementing a prospective surveillance and early intervention model of care for breast cancer\u2013related lymphedema into clinical practice: application of the RE-AIM framework. Support Care Cancer. 2021;29:1081\u20139.","journal-title":"Support Care Cancer"},{"issue":"6","key":"17854_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1089\/lrb.2021.0084","volume":"20","author":"SH Ridner","year":"2022","unstructured":"Ridner SH, Dietrich MS, Boyages J, et al. A comparison of bioimpedance spectroscopy or tape measure triggered compression intervention in chronic breast cancer lymphedema prevention. Lymphat Res Biol. 2022;20(6):618\u201328.","journal-title":"Lymphat Res Biol."},{"key":"17854_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06850-7","volume":"198","author":"C Shah","year":"2023","unstructured":"Shah C, Whitworth P, Valente S, et al. Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. Breast Cancer Res Treat. 2023;198:1\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"17854_CR9","doi-asserted-by":"publisher","first-page":"1062472","DOI":"10.3389\/fonc.2022.1062472","volume":"12","author":"MP McEvoy","year":"2022","unstructured":"McEvoy MP, Gomberawalla A, Smith M, et al. The prevention and treatment of breast cancer- related lymphedema: a review. Front Oncol. 2022;12:1062472.","journal-title":"Front Oncol."},{"key":"17854_CR10","first-page":"102441","volume":"68","author":"HCY Wong","year":"2024","unstructured":"Wong HCY, Wallen MP, Chan AW, et al. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidance for the prevention of breast cancer-related arm lymphoedema (BCRAL): international Delphi consensus-based recommendations. EClin Med. 2024;68:102441.","journal-title":"EClin. Med."},{"key":"17854_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12032-024-02510-6","volume":"41","author":"CL Brunelle","year":"2024","unstructured":"Brunelle CL, Jackson K, Shallwani SM, et al. Evidence-based recommendations regarding risk reduction practices for people at risk of or with breast cancer-related lymphedema: consensus from an expert panel. Med Oncol. 2024;41:298.","journal-title":"Med Oncol."},{"issue":"4","key":"17854_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ijrobp.2020.10.024","volume":"109","author":"J Boyages","year":"2021","unstructured":"Boyages J, Vicini FA, Shah C, et al. The risk of subclinical breast cancer-related lymphedema by the extent of axillary surgery and regional node irradiation: a randomized controlled trial. Int J Radiat Oncol Biol Phys. 2021;109(4):987\u201397.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"17854_CR13","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1002\/cncr.34377","volume":"128","author":"LA Koelmeyer","year":"2022","unstructured":"Koelmeyer LA, Gaitatzis K, Dietrich MS, et al. Risk factors for breast cancer\u2013related lymphedema in patients undergoing 3 years of prospective surveillance with intervention. Cancer. 2022;128:3408\u201315.","journal-title":"Cancer"},{"key":"17854_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1200\/OP.23.00060","volume":"19","author":"Boyages John","year":"2023","unstructured":"John Boyages, et al. Axillary treatment and chronic breast cancer\u2013related lymphedema: implications for prospective surveillance and intervention from a randomized controlled trial. JCO Oncol Pract. 2023;19:1116\u201324.","journal-title":"JCO Oncol Pract."},{"key":"17854_CR15","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1245\/s10434-024-15706-x","volume":"31","author":"C Shah","year":"2024","unstructured":"Shah C, Boyages J, Koelmeyer L, et al. Timing of breast cancer related lymphedema development over 3 years: observations from a large, prospective randomized screening trial comparing bioimpedance spectroscopy (BIS) versus tape measure. Ann Surg Oncol. 2024;31:7487\u201395.","journal-title":"Ann Surg Oncol."},{"key":"17854_CR16","first-page":"85","volume":"46","author":"MR Fu","year":"2013","unstructured":"Fu MR, Cleland CM, Guth A, et al. L-Dex ratio in detecting breast cancer-related lymphedema: reliability, sensitivity, and specificity. Lymphology. 2013;46:85\u201396.","journal-title":"Lymphology."},{"issue":"12","key":"17854_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1080\/0284186X.2016.1191668","volume":"55","author":"ES Dylke","year":"2016","unstructured":"Dylke ES, Schembri GP, Bailey DL, et al. Diagnosis of upper limb lymphedema: development of an evidence-based approach. Acta Oncol. 2016;55(12):1477\u201383.","journal-title":"Acta Oncol"},{"issue":"4","key":"17854_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1089\/lrb.2016.0001","volume":"14","author":"SH Ridner","year":"2016","unstructured":"Ridner SH, Dietrich MS, Niermann K, et al. A prospective study of the lymphedema and fibrosis continuum in patients with head and neck cancer. Lymphat Res Biol. 2016;14(4):198\u2013205.","journal-title":"Lymphat Res Biol."},{"key":"17854_CR19","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer V.3.2025. National Compreshensive Cancer Network, Inc. 2025. Accessed April 17, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org"},{"key":"17854_CR20","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship V.1.2025. National Comprehensive Cancer Network, Inc. 2025. Accessed April 17, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17854-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17854-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17854-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:07:00Z","timestamp":1759507620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17854-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17854"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17854-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.C. is an employee of ImpediMed. C.S. reports consulting fees (e.g., advisory boards) from ImpediMed, consulting fees (e.g., advisory boards) from PreludeDx, and consulting fees (e.g., advisory boards) from Videra Surgical. J.B. is a stockholder of ImpediMed. L.K. reports grant\/research support from ImpediMed. F.A.V. reports consulting fees (e.g., advisory boards) from ImpediMed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}